There is not much to talk about. The last discussion by AGN was at the March Conf Call.
If you go to Market Watch, you can find the following: type this header
US Breast Implant Device Market to Continue Modest Growth, While European Market Remains Flat Through 2016
In contrast to implants, the acellular dermal matrix segment has a significant number of competitors," said MRG Analyst Kristina Vidug. "Most of these companies also compete in the soft tissue repair device market, and leverage their existing brand identities when entering the breast implant device market. LifeCell is the largest competitor, with dominance in both allografts and xenografts. Allergan is expected to enter this segment with its SeriScaffold product in 2013.